We've had Eyes on the evolving Pharma Pipeline Strategy. This week we highlight how many companies are leaning on external innovation with full acquisition s to targeted asset deals to drive long-term strategy.

This week, following up on our recent post about Merck, we had Eyes On their recent bid for Cidara Therapeutics. This time, the acquisition is made to diversify their portfolio further, adding an antiviral asset for Influenza prophylaxis. This asset, CD 388, could provide a new class of prophylaxis, outside of the current vaccines area.